amylin glp 1 dual agonist Amycretin vs CagriSema: Unimolecular vs Combination GLP-1/Amylin Therapy - Which Is Better? | PPW Amycretin — a novel obesity

Background Observations from phase-3 clinical trials like SUSTAIN and PIONEER indicated anti-obesity potential of semaglutide, which was established in STEP trials

Market analysts anticipate eight or more novel GLP-1-based approvals for chronic weight management over the next four years, as the drug class extends from its metabolic origins into a broader platform for addressing diseases with underlying inflammatory and cardiometabolic components

Scand J Gastroenterol 31: 665-670, 1996

But thats the extent of data we have for the 104 week arm, everything else is 80 week data, so lets look at differences in weight loss in male vs female patients

Nutritional shifts play a big role